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Abstract
Aims Takotsubo syndrome (TTS) episodes are primarily initiated by ‘pulse’ release of catecholamines inducing neutrophil in-
filtration and myocardial inflammation in susceptible individuals (largely ageing women). Evidence of myocardial inflammation
and associated energetic impairment persists for ≥ 3 months post-acute TTS episodes, suggesting the existence of additional
‘perpetuating’ mechanisms. The effects of B-type natriuretic peptide (BNP) in suppressing superoxide (O2
) release from neu-
trophils are transiently impaired in acute heart failure. We also evaluated the extent and duration of BNP-induced suppression
of O2
 release post-TTS.
Methods and results TTS patients were studied acutely (n = 34) and 3months thereafter (n = 13) and compared with control
subjects (n = 25). O2
 generation from neutrophils, triggered by N-formyl-methionyl-leucyl-phenylalanine and phorbol
myristate acetate, and its suppression by BNP, were measured in vitro. Determinants of variability in BNP effect were sought
via univariate and multivariate analyses.
Relative to control subjects, in TTS patients, BNP suppression of both phorbol myristate acetate and N-formyl-methionyl-
leucyl-phenylalanine-induced O2
 release was impaired acutely (P < 0.05 for both); this did not improve over the 3-month re-
covery period, despite treatment with conventional anti-failure medication in 85% of patients. No significant correlates of BNP
effect (other than TTS) were identified.
Conclusions (1) While TTS is associated with marked and prolonged release of BNP, there is virtually total loss of the ability
of BNP to suppress neutrophil O2
 release and its impact on tissue inflammation. (2) BNP responses do not recover for at
least 3 months post-attacks, suggesting that this might contribute to perpetuation of myocardial inflammation in TTS
patients.
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Introduction
Takotsubo syndrome (TTS), also called stress-induced
cardiomyopathy, apical ballooning syndrome, or broken
heart syndrome, usually presents with chest pain of acute
origin.1,2 TTS occurs predominantly in ageing women,
and episodes of chest pain corresponding to the onset of
TTS are usually associated with emotionally or physically
stressful events. Irrespective of symptoms, the diagnosis
of TTS tends to be made on the basis of transient segmen-
tal left ventricular (LV) wall motion abnormalities particu-
larly involving the LV apex or mid-ventricle without
corresponding obstructive coronary artery disease.2 Al-
though the syndrome was first recognized and reported
by a Japanese group,3 it is now accepted that TTS occurs
frequently in Caucasian populations and indeed that it ac-
counts for up to 10% of ‘heart attacks’ in women aged
over 50 years.4
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The pathophysiology of TTS syndrome remains incom-
pletely elucidated at present. Among pathophysiological
mechanisms that have been proposed are multivessel coro-
nary vasospasm, abnormalities in coronary microvascular
function or spasm, catecholamine-mediated myocardial ‘stun-
ning’, coronary emboli with spontaneous fibrinolysis, and/or
transient obstruction of the LV outflow tract.2,5 However,
more recently, it has emerged that TTS is primarily an inflam-
matory ‘myocarditis’, with cardiac MRI investigations reveal-
ing extensive, although mainly apical, oedematous reactions.6
The cause of inflammation in TTS is at present not well de-
lineated. However, excessive release of catecholamines7 has
been suggested to induce redox stress via release of reactive
oxygen species and to promote inflammatory processes,
resulting in myocyte dysfunction and apoptosis. Apart from
cardiac magnetic resonance imaging scanning,8 inflammation
has been documented directly via endomyocardial biop-
sies.7,9,10 Experimentally, a British group has provided evi-
dence that TTS may be triggered by β2-adrenoceptor
stimulation and Gi-based signalling but did not delineate the
basis for inflammatory activation.11 Recent evidence, predom-
inantly from studies in rodent models of TTS, has implicated
the generation of peroxynitrite12,13 and cellular infiltration
with neutrophils and macrophages12,13 in the pathogenesis
of myocardial inflammation in TTS.
A number of investigations have reported markedly ele-
vated plasma levels of B-type natriuretic peptide (BNP)14,15
or N terminal (NT)-proBNP16 despite the fact that the LV fill-
ing pressure is not generally elevated in TTS.17,18 The marked
and persistent elevation of NT-proBNP/BNP levels in TTS re-
flects both the extent of catecholamine increase and the se-
verity of LV systolic dysfunction.19 Furthermore, a study
conducted by Morel et al.20 demonstrated that in TTS pa-
tients, inflammatory activation was directly related both to
the extents of impairment of LV function and neurohormonal
activation. For example, C-reactive protein (CRP) levels were
inversely correlated to LV ejection fraction (LVEF) and directly
to BNP levels, while plasma leukocyte counts were directly
correlated to both BNP and noradrenaline levels.20 These
data extend the argument that the predominant stimulus
for BNP release in TTS is inflammatory rather than myocardial
distension.
We have shown that BNP inhibits superoxide (O2
) gener-
ation in stimulated neutrophils of healthy subjects and that
this effect is attenuated during the acute stages of heart
failure patients.21 Given that NT-proBNP and BNP levels
are substantially elevated in the acute stages of both HF
and TTS patients as well,19 the question arises: ‘Does in-
creased BNP release “automatically” down-regulate neutro-
phil response?’ Therefore, the objective of the present
study was to determine (i) whether BNP-induced suppres-
sion of neutrophil O2
 release is also present during the
acute stages of TTS; and (ii) what are the determinants of
BNP effect in individual patients with TTS.
Methods
Study cohort
Patients with TTS were prospectively identified according to
the Mayo Clinic criteria.22 The study was approved by the in-
stitutional Ethics of Human Research Committee of The
Queen Elizabeth Hospital (Adelaide, Australia), and informed
consent was obtained prior to study entry.
All TTS patients underwent routine clinical assessment on
admission, including ECG monitoring, and regular monitoring
of heart rate, blood pressure and oxygenation, transthoracic
echocardiography, and coronary angiography. Additionally,
blood samples were taken for determination of NT-proBNP
and hs-CRP levels. Plasma levels of the endogenous catechol-
amine metabolites, metanephrine, and normetanephrine
were determined at the time of diagnosis as previously
outlined.19
Control subjects (without known heart diseases) were se-
lected via advertisement and had blood samples taken sub-
ject to informed consent.
All acute TTS patients had blood taken for neutrophil eval-
uation at admission post-onset of symptoms. Patients were
re-approached for evaluation of BNP response in neutrophils
at a median of 3 months post-onset of symptoms.
Blood sampling and preparation of neutrophils
Blood samples were drawn by venesection from an
antecubital vein. Blood was collected into heparinized
vacutainer tubes for plasma collection or into 24 mmol/L
EDTA for neutrophil preparation as described previously.21
For platelet aggregation studies, blood was collected into
plastic tubes containing 1:10 volume of citrate anticoagulant
(two parts of 0.1 M citric acid and three parts of 0.1 M
trisodium citrate, pH 5).
Electron paramagnetic resonance spectroscopy
measurement of reactive oxygen species
For O2
 determination by electron paramagnetic resonance
(EPR), neutrophils were incubated with BNP (1 μmol/L) for
10 min and then stimulated with either PMA (100 nmol/L,
for 20min) or fMLP (1 μmol/L). Samples were scanned imme-
diately after supplementation of the spin probe 1-hydroxy-3-
methoxycarbonyl-2,2,5,5 tetramethyl pyrrolidine hydrochlo-
ride (CM-H, 200 μmol/L). EPR settings were the same as previ-
ously described.21 EPR experiments were performed in
triplicates.
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Assessment of platelet response to nitric oxide
(NO) donor sodium nitroprusside
Given that platelet responsiveness to the anti-aggregatory
effects of nitric oxide (NO) is impaired under oxidative
stress,23 we sought to compare integrity of platelet NO
and neutrophil BNP responses in both control subjects and
TTS patients. The NO donor sodium nitroprusside (SNP,
10 μmol/L) was utilized to quantitate platelet responsiveness
to NO, expressed as percent inhibition of ADP-induced
(2.5 μmol/L) platelet aggregation in whole blood, as previ-
ously described.24
Chemicals
BNP was purchased from BACHEM (Bubendorf,
Switzerland). Stock solution was prepared with deoxygen-
ated Milli-Q water, aliquoted and stored at 80°C. CM-H
was purchased from NOXYGEN (Elzach, Germany). Stock so-
lutions of CM-H (400 mmol/L) were prepared in DMSO and
kept at 20°C. Working solution of CM-H (2 mmol/L) was
prepared daily in Krebs-HEPES buffer. PMA, fMLP, and all
other reagents were obtained from Sigma-Aldrich (St. Louis,
MO, USA). Appropriate vehicle controls were performed.
Specifically, physiological effects of reagents reconstituted
in DMSO (PMA) or ethanol (fMLP), and further diluted with
HBSS to required concentrations, were assessed in parallel
with samples subjected to analogously diluted DMSO or
ethanol solutions. With reagent reconstituted in water
(BNP), relevant volumes of water were added to control
samples.
Data analysis
All normally distributed data are expressed as
means ± standard error of the mean. Statistical significance
was determined by Student’s t-test for paired normally dis-
tributed data. GraphPad Prism version 7 for Windows
(GraphPad Software, San Diego, CA) was used. Values of
P < 0.05 were considered statistically significant.
Comparisons were made between TTS patients (n = 34)
and control subjects (n = 25, aged > 40 years). Impact of
increasing age was compared using Pearson’s correlation
coefficient and two-way ANOVA. The relationship between
SNP responsiveness in platelets (a measure of integrity of
soluble guanylate cyclase function) and BNP suppression
of PMA-related O2
 release (reflecting particulate guanylate
cyclase function) was evaluated via linear regression for
both TTS patients and control subjects. In order to evaluate
the time course of putative changes in BNP response in
TTS, we correlated duration of symptoms (from the time
of onset of symptoms till blood sampling) with BNP
response. Also, correlations were sought between BNP re-
sponse and the following parameters: plasma NT-proBNP
levels, peak troponin T concentrations, LVEF, lowest systolic
blood pressure on admission, normetanephrine release, and




The clinical characteristics of the 34 acute TTS patients
and 25 controls are summarized in Table 1. All patients
were aged > 40 years, and none had evidence of pulmonary
congestion, although LV systolic function varied substan-
tially. One control subject had uncomplicated diabetes
mellitus.
Mean age of the TTS cohort was significantly greater than
that of the control subjects (mean ages, 70 ± 2 and 60 ± 2 years,
respectively; P < 0.01). Furthermore, only 69% of the control
subjects were females. Patients diagnosed with TTS were rou-
tinely treated with intravenous heparin infusion for at least
24 h.
Evaluation occurred 0.5 to 5.5 days post-onset of symp-
toms: this corresponded to marked but variable evaluation
of NT-proBNP and hs-CRP concentrations, with 10 of the 34
patients already receiving angiotensin converting enzyme
inhibitors at the time of blood sampling.
Table 1 Clinical characteristics of Takotsubo syndrome patients at
admission vs. controls
TTS patients (N = 34) Control (N = 25)
Age (years ± SEM) 72 ± 2 60 ± 2*






97 ± 3 N/A
Peak troponin
T (ng/L)
458 ± 59 N/A














ACE: angiotensin converting enzyme; BP: blood pressure; F: female;
hs-CRP: high sensitivity C-reactive protein; LVEF: left ventricular
ejection fraction; M: male; SEM: standard error of the mean; TTS:
takotsubo syndrome.
*P < 0.001
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 content did not vary significantly be-
tween control subjects and acute TTS patients; neither did
O2
 release stimulated with PMA or fMLP significantly differ
between control and patients. With regard to the impact of
BNP in suppressing PMA-induced and fMLP-induced O2
 re-
lease in TTS patients, significant attenuation was observed
compared with control subjects (Figure 1): in general, there
was no suppression of O2
 release in the TTS population.
Mean suppression values for each stimulant were, (i) for
PMA: 16.2 ± 3.6% for controls vs. 0.03 ± 3.2% for TTS patients
(P = 0.002); and (ii) for fMLP: 18.1 ± 5.7% for controls vs.
3.4 ± 7.8% for TTS patients (P = 0.046). In controls, BNP ef-
fects were gender independent (data not shown). In patients
with TTS, BNP suppression tended to increase with patients’
age (r = 0.37, P = 0.03). This trend was absent in controls
but the age: BNP interaction did not vary significantly accord-
ing to disease state (Figure 2; ANOVA: F = 1.06, P = 0.435 for
interaction).
Correlations of clinical parameters with BNP
effects
Among TTS patients, no univariate correlations were ob-
served between BNP responses and normetanephrine or
metanephrine concentrations, minimal systolic blood pres-
sure, hs-CRP, LVEF, troponin T, and peak NT-proBNP levels.
Furthermore, duration of symptoms (2.5 ± 0.3 days) also
was not a significant univariate determinant of BNP response.
If normetanephrine concentrations, minimal systolic blood
pressure, LVEF, troponin T, peak NT-proBNP levels, and utili-
zation of angiotensin converting enzyme inhibitors were
forced into backwards stepwise multiple logistic regression
model, none of these represented an independent correlate
of BNP response among TTS patients (data not shown).
Comparison with nitric oxide (NO) signalling
In order to determine whether mechanisms and extent of
BNP resistance in individual patients overlapped with those
of platelet NO resistance,21,23 correlations between these
two parameters were sought. In control subjects (Figure 3),
BNP suppression of neutrophil O2
 release varied directly with
anti-aggregation responses to SNP. This trend was blunted in
TTS patients (NS: data not shown).
Impact of treatment of Takotsubo syndrome
Acute TTS patients, 13 were re-evaluated after at least
3 months’ recovery. Simultaneous NT-proBNP concentration
was 192 pg/mL (median, P = 0.002 vs. acute phase but still el-
evated above normal concentrations). BNP suppression of O2

release was still impaired (Figure 4): 1.3 ± 5.2% acutely vs.
2.2 ± 3.0% on follow-up for PMA stimulation (P = 0.9); and
2.9 ± 14.0% acutely vs. 14.4 ± 7.8% on follow-up for fMLP
stimulation (P = 0.5).
Figure 1 Effect of BNP (1 uM) on neutrophil O2
 generation in response to (A) PMA (P = 0.002) and (B) fMLP (P = 0.046) in control subjects and
Takotsubo syndrome patients during index admission. Both PMA-related and fMLP-related data in controls were gender independent.
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Discussion
We have previously obtained data suggesting that BNP is a
physiologically relevant suppressant of neutrophil O2
 re-
lease.25 As such, BNP might play a role in limiting the poten-
tial for extensive extracellular redox stress induced by
neutrophil NADPH oxidase activation. However, these effects
are substantially attenuated in patients with acute heart fail-
ure,21 raising the possibility that this ‘BNP resistance’ might
contribute to the extent of acute tissue (including myocardial)
injury under those circumstances. The duration of BNP resis-
tance was< 3months in that study, although it remained un-
clear whether the efflux of time or the initiation of treatment
has restored BNP responses. Interestingly, in this heart failure
cohort, NT-proBNP concentrations fell minimally with time,
suggesting that plasma BNP concentrations were not the pri-
mary modulators of neutrophil BNP responses.
TTS can also be viewed as a ‘heart failure syndrome’,26 al-
though it usually presents as pseudo-acute myocardial infarc-
tion. BNP release is initially very considerable and may be
triggered primarily by the intense underlying myocardial in-
flammation12 rather than regional stretch. Furthermore, many
TTS patients develop severe hypotension within 24 h of onset
of symptoms,27 and a role of BNP in this process has never
been excluded. Hence, it is of at least theoretical interest
whether the BNP released in TTS retains its physiological
activities.
In the current study, we tested the hypothesis that the
anti-inflammatory effects of BNP are intact in TTS. Actually,
such effects measured in neutrophils were virtually
Figure 2 Correlation between age and extent of BNP effects on neutrophil O2

generation in response to PMA. Two-way ANOVA: F = 1.06, P = 0.435 for
interaction.
Figure 3 Correlations between BNP effects in isolated neutrophils and platelet response to sodium nitroprusside measured in whole blood of control
subjects. The 19 control subjects evaluated in this way were chosen irrespective of age. r = 0.456, P = 0.0496.
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abolished, both acutely and after approximately 3 months
follow-up. Thus, TTS patients differ from those with acute
heart failure, with prolonged suppression of BNP signalling.
Notably, attenuation of BNP effects became less obvious
as TTS patients aged.
It is important that both causes and consequences of the
currently observed impairment of BNP responsiveness in
neutrophils be considered. It must be stated that the pre-
cise cause has not been identified at this stage. We have
previously explored the signal transduction pathway
whereby BNP normally limits O2
 release within the neutro-
phil burst,28 and it follows from this that diminished cGMP
release in response to BNP (‘BNP resistance’) implies a res-
toration of NAD(P)H oxidase assembly and resultant O2
 re-
lease. The resultant oxidative stress may contribute to the
generator of peroxynitrite, which appears pivotal to inflam-
matory activation in TTS.12,29 Irrespective of mechanisms,
the immediate consequence of impaired BNP effect, and
consequent failure to suppress inflammation, may include
aggravation of myocardial inflammation, which is prominent
in both clinically based studies30,31 and animal models of
TTS.12,13
In TTS, neutrophil infiltration of the myocardium occurs
particularly during the first few days and thereafter is much
less prominent.13 Thus, it is uncertain whether the continu-
ation of neutrophil resistance to BNP carries the same im-
pact on myocardial inflammatory state after the first few
days. Nevertheless, it is likely that BNP resistance (which
can theoretically occur within myocardium as well as neutro-
phils) contributes to ongoing inflammation12 post-TTS. In
theory, persistent impairment of BNP effect in patients
with TTS might contribute towards slow resolution of myo-
cardial inflammation and therefore predispose towards slow
recovery of LV systolic function. Unfortunately, too few pa-
tients in the current series had simultaneous follow-up
echocardiography and determination of BNP effects in neu-
trophils for a correlation analysis to be performed.
It should be noted that the current experiments have not
evaluated the potential vasoconstrictor implications of BNP
resistance in TTS or the possibility that it serves to limit hypo-
tensive crises in the early stages post-onset of TTS. Further-
more, accentuation of BNP responses in control subjects
with advancing age remains unexplained; on the other hand,
the current data are clear-cut evidence that suppression of
neutrophil BNP response is not purely a consequence of
prolonged accentuated BNP release.
In conclusion, the current studies show that TTS represent
a condition of longstanding resistance to the
anti-inflammatory effects of BNP. Further studies will be
needed to determine whether this concept of ‘vulnerable
neutrophils’ should be coupled with the potential of a ‘cate-
cholamine pulse’ in activating inflammation, as the overall
initiating stimulus in TTS.
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